Please use this identifier to cite or link to this item:
|Title:||Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung||Authors:||De Lima Lopes Jr., G.
epidermal growth factor receptor
|Issue Date:||15-Feb-2012||Citation:||De Lima Lopes Jr., G., Segel, J.E., Tan, D.S.W., Do, Y.K., Mok, T., Finkelstein, E.A. (2012-02-15). Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung. Cancer 118 (4) : 1032-1039. ScholarBank@NUS Repository. https://doi.org/10.1002/cncr.26372||Abstract:||Background: Epidermal growth factor receptor (EGFR) testing and first-line therapy with gefitinib for patients with activating mutations is quickly becoming the standard option for the treatment of advanced lung adenocarcinoma. Yet, to date, little is known about the cost-effectiveness of this approach. Methods: A decision-analytic model was developed to determine the cost-effectiveness of EGFR testing and first-line treatment with gefitinib for those patients who harbor activating mutations versus standard care, which includes first-line treatment with chemotherapy followed by gefitinib as second-line treatment. The model uses clinical and outcomes data from randomized clinical trials and societal costs from Singapore cancer centers. Health effects were expressed as quality-adjusted life-years. All costs and cost-effectiveness ratios were expressed in 2010 Singapore dollars. Sensitivity and different scenarios analyses were conducted. Results: EGFR testing and first-line treatment with gefitinib is a dominant strategy (with lower costs and greater effectiveness) compared with standard care. Because the primary savings result from not providing gefitinib to those who are not likely to benefit, this finding holds regardless of the prevalence of activating mutations. In a secondary analysis, first-line treatment with gefitinib was also dominant when compared with first-line chemotherapy in patients with activating EGFR mutations. Conclusions: This strategy can be considered a new standard of care and should be of great interest for health care payers and decision makers in an era in which our greatest challenge is to balance hard-won and incremental, yet small, improvements in patient outcomes with exponentially rising costs. © 2011 American Cancer Society.||Source Title:||Cancer||URI:||http://scholarbank.nus.edu.sg/handle/10635/124662||ISSN:||0008543X||DOI:||10.1002/cncr.26372|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on May 28, 2020
WEB OF SCIENCETM
checked on May 20, 2020
checked on May 29, 2020
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.